Jump to content
Advertisement

Advertisement

Pubmed-Psychopharmacologic Therapies for Irritable Bowel Syndrome


Health Reporter
 Share

Recommended Posts


Advertisement

Gastroenterol Clin North Am. 2021 Sep;50(3):655-669. doi: 10.1016/j.gtc.2021.04.005. Epub 2021 Jul 1.

ABSTRACT

Psychopharmacologic therapies are beneficial in reducing symptoms when treating irritable bowel syndrome (IBS) and other disorders of gut-brain interaction (DGBI). Noradrenaline, serotonin, and dopamine are neurotransmitters of key importance in psychopharmacology and pain-reduction mechanisms. The first-line (tricyclic antidepressants, serotonin noradrenaline reuptake inhibitors, selective serotonin reuptake inhibitors) and second-line (atypical antipsychotics, delta-ligand agents, low-dose naltrexone) neuromodulator treatment options are recommended when IBS-associated abdominal pain is of moderate or severe intensity and is persistent. To understand the implementation strategy, the multidimensional clinical profile as a template is used for presenting 3 case scenarios involving painful IBS and DGBI of varying complexity.

PMID:34304793 | DOI:10.1016/j.gtc.2021.04.005

View the full article



Advertisement
Link to post
Share on other sites

 Share

×
×
  • Create New...